AIV-001 is under clinical development by AiViva BioPharma and currently in Phase II for Basal Cell Carcinoma (Basal Cell Epithelioma). According to GlobalData, Phase II drugs for Basal Cell Carcinoma (Basal Cell Epithelioma) have a 50% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AIV-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AIV-001 overview

AIV-001 is under development for the treatment of scar, low-risk basal cell carcinoma, wounds and Nonmelanoma skin cancer. The drug candidate is formulated as suspension and administered through intradermal route for wound healing. It was also under development for  papulopustular rosacea.

AiViva BioPharma overview

AiViva BioPharma (AiViva) is a clinical-stage biotech company that develops drug products with the potential to profoundly reduce the treatment burden for patients and physicians and which may transform current treatment paradigms. AiViva is headquartered in Newport Beach, California, the US.

For a complete picture of AIV-001’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.